4-Step Renal Dosimetry Dependent on Cortex Geometry Applied to ⁹⁰Y Peptide Receptor Radiotherapy: Evaluation Using a Fillable Kidney Phantom Imaged by ⁹⁰Y PET

Abstract

Accurate dosimetry in 90 Y peptide receptor radionuclide therapy (PRRT) helps to optimize the injected activity, to prevent kidney or red marrow toxicity, while giving the highest absorbed dose to tumors. The aim of this study was to evaluate whether direct 90 Y bismuth germanate or lutetium yttrium orthosilicate time-of-flight PET was accurate enough to provide dosimetry estimates suitable to 90 Y PRRT. Method: To overcome the statistical uncertainty arising from the low 90 Y positron counting rate, the computation of the cortex mean-absorbed dose was divided into 4 steps: delineation of the cortex volume of interest (VOI) on the CT scan, determination of the recovery coefficient from the cortex VOI using the point-spread function of the whole imaging process, determination of the mean cortex-absorbed dose per unit cumulated activity in the cortex (S cortex)cortex value) from the cortex VOI using a 90 Y voxel S value kernel, and determination of the number of decays in the cortex VOI from the PET reconstruction. Our 4-step method was evaluated using an anthropomorphic abdominal phantom containing a fillable kidney phantom based on the MIRD kidney model. Vertebrae with an attenuation similar to that of bone were also modeled. Two tumors were modeled by 7-mL hollow acrylic spheres and the spleen by a plastic bag. Activities corresponded to typical tissue uptake in a first 90 Y-DOTATOC cycle of 4.4 GBq, considered as free of significant renal toxicity. Eight successive 45-min scans were acquired on both systems. Results: Both PET systems were successful in determining absorbed dose to modeled tumors but failed to provide accurate red marrow dosimetry. Renal cortex dosimetry was reproducible for both PET systems, with an accuracy of 3% for the bismuth germanate system but only 18% for the lutetium yttrium orthosilicate time-of-flight system, which was hindered by the natural radioactivity of the crystal, especially in the most attenuated area of the kidney. Conclusion: This study supports the use of direct 90 Y PET of the first PRRT cycle to assess the kidney-absorbed dose and optimize the injected activity of the following cycles.Key Words: PET/CT; radiobiology/dosimetry; radionuclide therapy; PET; PRRT; dosimetry; kidney; 90 Y J Nucl Med 2010; 51:1969 51: -1973 51: DOI: 10.2967 Pept ide receptor radionuclide therapy (PRRT) with 90 Y is widely used for internal radiotherapy of neuroendocrine tumors (1). 90 Y has a long b 2 range that, although suboptimal for small tumors, irradiates rather uniformly larger tumors that often display heterogeneous perfusion. This irradiation ability was confirmed in an animal model, in which a combination of 90 Y-and 177 Lu-labeled somatostatin analog showed a better tumor response than either radioisotope alone (2). Used alone, 90 Y PRRT is frequently administrated in several cycles. The dose fractionation has proven less toxic for the kidney (3) because it allows DNA repair in normal tissues between cycles, without a noticeable reduction of the tumor response (4).Assessment of...

177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma

“…90 Y is a pure b-emitter, and therefore dosimetry and imaging have historically required concurrent administration of 111 In-DTPA-D-Phe 1 -octreotide whereas 177 Lu-DOTATATE emits g-and b-radiation, allowing essential dosimetry measurements and imaging to be performed from the same administration. There have been reports on the feasibility of 90 Y PET/CT; the main limitation is the data acquisition time (33,34).…”

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

“…Although primarily used to evaluate radiation dose from 90 Y-microsphere therapy [76], it is also possible to assess dose delivered by doing post-treatment PET/CT [77]. While not widely available, it is also possible to perform prospective dosimetry by using PET/CT with 86 Y-labelled ligands [78] or by extrapolating from co-administered 111 In-DTPA-octreotide [79].…”

Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy

“…90 Y-PET acquisition has been shown to be feasible for dosimetry assessment after liver SIRT in an anatomical phantom as well as in a patient [39,40]. In a phantom study, Walrand et al found that 90 Y-DOTATOC PET can be used for kidney dosimetry, but this is currently not being done on patient data [41]. This has to be further explored.…”